Who we are?

Receptor.AI is a pioneering TechBio company transforming drug discovery through a validated, AI-powered multiplatform ecosystem. We specialize in developing advanced platforms that address the most complex and previously "undruggable" targets with first-in-class therapeutic modalities, ensuring precision and innovation at every step.

We are committed to making early-stage drug discovery significantly faster and more cost-effective, empowering researchers to achieve breakthroughs with confidence. Our ecosystem drives innovations that directly impact healthcare by targeting diseases with high unmet needs. Working on diverse, high-impact drug discovery projects, we rigorously test and refine our platforms, ensuring we deliver state-of-the-art capabilities informed by unparalleled industry experience.

Receptor.AI is a team of seasoned scientists, engineers, and industry experts dedicated to revolutionizing drug discovery with combined expertise and shared vision. We are strongly confident that technological innovation in drug design will radically change our civilization in the near future.

Our Timeline

Company Incorporation

Our tech-bio company was founded in Kyiv with a team of 15 experts specializing in medicinal chemistry and AI, aiming to develop a best-in-class AI-driven drug discovery platform.

Q1 2021

Validation of Platform MVP

We completed our first MVP case study, focusing on targeting BRD4 and SIRT1 proteins in collaboration with a leading CRO.

Q3 2021

Leading AI Models for Drug Discovery

We developed the second generation of AI models, including our core semi-ligand-based model, 3DProtDTA, and a Multitask ADMET model with 35 parameters.

Q4 2021

Platform Development

We launched the first version of our SaaS platform, establishing the foundation for scalable drug discovery solutions.

Q2 2022:

Commercial Milestone

We secured our first commercial project, marking a significant milestone in our market entry.

Q3 2022

Relocation of Headquarters

Our headquarters were relocated to London, with key employees and R&D operations moving to Central Europe.

Q3 2022

Lead Optimization Initiatives

We initiated our first lead optimization stage project, further enhancing our track record and expertise.

Q4 2022

Development of Selectivity Platform

We successfully developed our selectivity platform, expanding our capabilities in targeting difficult-to-drug proteins.

Q4 2022

Achieving IND-Stage

We completed our first IND-stage project, focusing on developing lipid formulations for TLR agonists.

Q1 2023

Customer Success and Strategic Partnerships

We entered our first partnership with a mid-sized pharmaceutical company and reached a total of 15 commercial drug discovery projects.

Q3 2023

Best AI docking outperforming AlphaFold

We developed ArtiDock, a best-in-class AI docking model that outperforms all conventional and AI docking techniques, including AlphaFold.

Q4 2023

Partnership with Nvidia and Peptide Drug Discovery

We partnered with Nvidia to enhance our generative AI capabilities and launched our first medium pharma project focused on peptide drug discovery.

Q1 2024

Strategic Big Pharma Partnership

We established a key partnership with a major pharmaceutical company, concentrating on membrane mitochondrial kinases.

Q2 2024

Innovations in PPIs and Induced Proximity

We developed a template-agnostic model for PPI targeting and integrated it into workflows for designing induced proximity compounds.

Q3 2024

Operational Excellence

We initiated 40 drug discovery projects, achieving an 86% success rate for completed projects.

Q3 2024

Headquatering in the US

We expanded into the US market by opening a headquarters in Boston and growing our team to 35 members and extending our advisory board.

Q3 2024

Our team

Dr. Alan Nafiev

Chief Executive Officer,
Co-founder

Ph.D. holder in Data Science with expertise in leading AI-driven drug discovery projects. He specializes in designing cloud systems for life sciences, particularly focusing on AI-powered workflows. With a strong background in B2B start-ups, he brings valuable experience to the intersection of data science and the life sciences industry.

Dr. Sergii Starosyla

Chief Technical Officer,
Co-founder

PhD in Molecular Biology with over 15 years of experience in drug discovery and scientific software development. Medicinal chemist, expert in development of machine-learning models, algorithms for pharmacophore modelling and molecular docking. Author of number of patented anticancer and anti-microbic biologically active compounds.

Dr. Semen Yesylevskyy

Chief Scientific Officer, 
Co-founder

PhD, in biophysics. 20+ years of experience in molecular modelling, computational drug discovery and scientific software development. Author of unique techniques and algorithms in simulations of curved and asymmetric lipid membranes and assessment of drug-membrane interactions.

Dr. Nicolas Babault

Scientific Advisor, Drug Discovery

PhD in Biophysics & Biochemistry with 15+ years of R&D experience across Industry and Academia, spanning from experimental validation to leadership roles. Extensive expertise in developing and optimizing drug discovery platforms, with deep knowledge in hit discovery and lead optimization for small molecules, peptides, and oligonucleotides.

Dr. Elena Brin

Scientific Advisor, Pharmacology

PhD in Pharmacology with 20+ years of R&D experience in Biotech and Big Pharma. Specializes in oncology drug discovery, including targeted and immuno-oncology therapies. Proven leadership guiding teams from early discovery to IND submissions, contributing to approved drugs. Strong record in in vitro and in vivo study design and clinical-stage assay development.

Prof. Kevin Burgess

Scientific Advisor, PPI Modulators

Renowned Rachal Professor of Chemistry at Texas A&M, who has made significant contributions to the fields of medicinal and combinatorial chemistry. He applies his expertise in peptido-mimetics, hybrid-peptides and PPI targeting.

Prof. Christophe Ramseyer

Scientific Advisor, Membrane Biophysics

PhD, Professor of Physics with 20+ years of experience in quantum chemistry and computational drug design. An expert in simulating interactions of theragnostic nanoparticles with the cell membrane.

Prof. Mikhail Bogdanov

Scientific Advisor, Membrane Molecular Biology

PhD, Professor of Biochemistry and Molecular Biology at University of Texas Medical School with 30+ years of experience in experimental studies of lipid membranes and membrane proteins. An expert in design and assessment of membrane targeting compounds.